. 2020 Feb 28;13(3):36. doi: 10.3390/ph13030036

Table 3.

Specificity and potency (in µM) of SC compounds against HIV-1J R-CSF, HIV-1 B41, HIV-1 HxBc2 Env, and HIV-1 AMLV pseudotyped HIV-1 using a single-round infection assay.

Compound	IC₅₀ JR-CSF	IC₅₀ B41	IC₅₀ HxBc2	IC₅₀ AMLV
SC11	0.0008 ± 0.0001	0.002 ± 0.0002	0.001 ± 0.0001	N.A.
SC12	0.008 ± 0.002	0.006 ± 0.003	0.080 ± 0.020	N.A.
SC15	0.003 ± 0.001	0.007 ± 0.001	0.009 ± 0.001	N.A.
SC28	0.096 ± 0.019	0.085 ± 0.03	0.069 ± 0.014	N.A.
SC45	0.224 ± 0.017	0.350 ± 0.030	0.380 ± 0.030	N.A.

N.A. = not active; N.D. = not determined.